SCHEMBL7219648

SCHEMBL7219648

CO/N=C1\C[C@@H](C(=O)N[C@@H](CO)c2ccccc2)N(C(=O)c2ccc(-c3ccccc3C)cc2)C1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OXTR P30559 5/20 0.75
AVPR1A P37288 5/20 0.75
AVPR2 P30518 2/20 0.37
FFAR2 O15552 4/20 0.37
MAPK1 P28482 3/20 0.36
ROCK2 O75116 2/20 0.36
ROCK1 Q13464 2/20 0.36
MAPK13 O15264 1/20 0.36
RPS6KA5 O75582 1/20 0.36
MAP4K4 O95819 1/20 0.36
PAK4 O96013 1/20 0.36
PRKCG P05129 1/20 0.36
CDK1 P06493 1/20 0.36
PRKACA P17612 1/20 0.36
RPS6KB1 P23443 1/20 0.36
CDK2 P24941 1/20 0.36
AKT1 P31749 1/20 0.36
AKT2 P31751 1/20 0.36
CLK2 P49760 1/20 0.36
GSK3A P49840 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4943349 1.00 OXTR (0.75) OXTRAVPR1AAVPR2FFAR2MAPK1
SCHEMBL5742342 0.92 OXTR (0.71) OXTRAVPR1AMAPK1ROCK2ROCK1
SCHEMBL5743780 0.86 OXTR (1.00) OXTRAVPR1AAVPR2FFAR2ROCK2
SCHEMBL4943198 0.86 OXTR (1.00) OXTRAVPR1AAVPR2FFAR2ROCK2
SCHEMBL4936543 0.86 OXTR (1.00) OXTRAVPR1AAVPR2FFAR2ROCK2
SCHEMBL4940385 0.86 OXTR (1.00) OXTRAVPR1AAVPR2FFAR2ROCK2
SCHEMBL4936354 0.86 OXTR (1.00) OXTRAVPR1AAVPR2FFAR2ROCK2
SCHEMBL4936174 0.86 OXTR (1.00) OXTRAVPR1AAVPR2FFAR2ROCK2
SCHEMBL4942975 0.86 OXTR (1.00) OXTRAVPR1AAVPR2FFAR2ROCK2
SCHEMBL5743785 0.86 OXTR (1.00) OXTRAVPR1AAVPR2FFAR2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171309-A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors MERCK SERONO SA (CH) 2003-09-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171309-A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors SUCNR1, PYCR1, GLS OXTR 189/4885AVPR1A 1456/4885AVPR2 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.